Telomeres, Telomerase and Cancer.
Aging
Cancer
Epimutations
Stem cell turnover
Telomerase
Telomere erosion
Telomere length
Journal
Archives of medical research
ISSN: 1873-5487
Titre abrégé: Arch Med Res
Pays: United States
ID NLM: 9312706
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
28
07
2022
revised:
05
10
2022
accepted:
12
10
2022
pubmed:
6
11
2022
medline:
15
12
2022
entrez:
5
11
2022
Statut:
ppublish
Résumé
Telomeres and telomerase play a crucial role in human aging and cancer. Three "drivers" of human aging can be identified. The developmental program encoded in DNA is the primary determinant of lifespan. Faithful execution of the developmental program requires stability of the (epi-)genome which is challenged throughout life by damage to DNA as well as epigenetic 'scars' from error-free DNA repair and stochastic errors made during the establishment and maintenance of the "epigenome". Over time (epi-)mutations accumulate, compromising cellular function and causing (pre-)malignant alterations. Damage to the genome and epigenome can be considered the second "driver" of aging. A third driver of the aging process, important to suppress tumors in long-lived animals, is caused by progressive loss of telomeric DNA. Telomere erosion protects against cancer early in life but limits cell renewal late in life, in agreement with the Antagonistic Pleiotropy theory on the evolutionary origin of aging. Malignant tumors arise when mutations and/or epimutations in cells (clock 2) corrupt the developmental program (clock 1) as well as tumor suppression by telomere erosion (clock 3). In cancer cells clock 3 is typically inactivated by loss of p53 as well as increased expression of telomerase. Taken together, aging in humans can be described by the ticking of three clocks: the clock that directs development, the accumulation of (epi-)mutations over time and the telomere clock that limits the number of cell divisions in normal stem and immune cells.
Identifiants
pubmed: 36334946
pii: S0188-4409(22)00125-4
doi: 10.1016/j.arcmed.2022.10.004
pii:
doi:
Substances chimiques
Telomerase
EC 2.7.7.49
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
741-746Informations de copyright
Copyright © 2022. Published by Elsevier Inc.
Déclaration de conflit d'intérêts
Conflict of Interest The author is a founding shareholder of Repeat Diagnostics Inc., a company specializing in clinical telomere length measurements since 2006.